Injectable GLP-1 Medications

Click to select Patient or Prescriber Pages Directly
       

Semaglutide is a GLP-1 antagonist that has been used in patients with type 2 diabetes control their blood sugar for many years. It is marketed by Novo Nordisk as an injection as the drug Ozempic® and as an oral tablet as Rybelsus®. The FDA recently approved a new use for the drug, allowing it to help patients battling chronic weight management. This is the same injectable drug but marketed by Novo Nordisk as Wegovy®.

Late in 2023 the Food and Drug Administration approved Zepbound® (tirzepatide) injection for chronic weight management in adults with obesity and a BMI of 30 or over with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity.

The usage of GLP-1 receptor antagonist has grown worldwide which has now caused the FDA to declare a drug shortage of these medications. Due to this FDA declared drug shortage, we are able to offer a compounded injectable Semaglutide as well as a compounded injectable Tirzepatide which is produced by a FDA-registered out-sourcing facility to help patients gain access to these valuable medications.

With the use of any of these compounded GLP-1 medications, it is strongly advised that patients strive to clean up their diets, lower their caloric intake and increase their physical activities to achieve their desired weight goals if they are using these for weight loss.

Due to strong patient requests for these drugs, we now offer them as well as the compounded oral sub-lingual semaglutide that we have offered in the past. Please be advised that when these drugs are no longer in a FDA declared drug shortage state, the only injectables on the market will be the branded drugs that are FDA approved for use. We will always continue to offer the oral sublingual semaglutide in the event the drug shortage clears up. But for now, a prescriber can choose to write for either the compounded injectable GLP-1s or the oral sub-lingual semaglutide GLP-1.